National Research Corporation (NRC) compared with its closest peers (OABI, GRAL, HTFL, BDSX, PSNL): P/E 75.5 vs industry 28.3. Peer set by Business Services; 10 comparable business services companies. First-party data.
OmniAb and Medpace share National Research's sub-industry, commercial research labs.
| Company | Market Cap | P/E |
|---|---|---|
| OmniAb, Inc. (OABI) | $731.31M | -3.2 |
| GRAIL, Inc. (GRAL) | $3.46B | -7.7 |
| Heartflow, Inc. Common Stock (HTFL) | $4.35B | -9.2 |
| Biodesix, Inc. (BDSX) | $286.57M | -1.5 |
| Personalis, Inc. (PSNL) | $1.79B | -8.8 |
| Exagen Inc. (XGN) | $181.92M | -6.6 |
| BillionToOne, Inc. (BLLN) | $5.23B | 138.7 |
| Fulgent Genetics, Inc. (FLGT) | $550.99M | -13.3 |
| Medpace Holdings, Inc. (MEDP) | $16.55B | 33.7 |
| Castle Biosciences, Inc. (CSTL) | $1.02B | -46.9 |
| Stock P/E | 75.5 |
| Sector P/E (Technology) | 31.8 |
| Industry P/E (Business Services) | 28.3 |
| vs Sector | 137.2% |
| vs Industry | 166.7% |
NRC overview · NRC earnings · NRC financials · NRC KPIs · NRC documents · NRC ownership
Data sourced from U.S. SEC EDGAR filings and market data. Not personalized investment advice.